Federated Hermes’s Dicerna Pharmaceuticals, Inc. DRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-227,187
Closed -$4.58M 2370
2021
Q3
$4.58M Sell
227,187
-167,114
-42% -$4.61M 0.01% 844
2021
Q2
$14.7M Buy
394,301
+182,823
+86% +$5.6M 0.03% 556
2021
Q1
$5.41M Buy
211,478
+211,208
+78,225% +$5.39M 0.01% 832
2020
Q4
$6K Sell
270
-107,990
-100% -$2.38M ﹤0.01% 2040
2020
Q3
$1.95M Sell
108,260
-10,136
-9% -$210K ﹤0.01% 999
2020
Q2
$3.01M Sell
118,396
-38,209
-24% -$823K 0.01% 853
2020
Q1
$2.88M Sell
156,605
-206,111
-57% -$4.01M 0.01% 786
2019
Q4
$7.99M Buy
362,716
+228,929
+171% +$4.61M 0.02% 648
2019
Q3
$1.92M Buy
+133,787
New +$1.91M ﹤0.01% 1047
2019
Q2
Sell
-287,961
Closed -$4.22M 2255
2019
Q1
$4.22M Sell
287,961
-43,592
-13% -$501K 0.01% 828
2018
Q4
$3.54M Buy
331,553
+79,058
+31% +$1.04M 0.01% 840
2018
Q3
$3.85M Buy
252,495
+252,085
+61,484% +$3.67M 0.01% 880
2018
Q2
$5K Buy
+410
New +$5.15K ﹤0.01% 2025
2017
Q3
Sell
-541
Closed -$2K 2212
2017
Q2
$2K Sell
541
-1,000
-65% -$3.16K ﹤0.01% 2059
2017
Q1
$5K Hold
1,541
﹤0.01% 1949
2016
Q4
$4K Buy
1,541
+1,324
+610% +$4.71K ﹤0.01% 1975
2016
Q3
$1K Buy
+217
New +$761 ﹤0.01% 2094
2015
Q3
Sell
-67
Closed -$1K 2081
2015
Q2
$1K Sell
67
-264
-80% -$4.84K ﹤0.01% 1922
2015
Q1
$8K Buy
+331
New +$7.44K ﹤0.01% 1808

Other funds holding DRNA

Federated Hermes's DRNA Position: Q4 2021 in Review

Federated Hermes sold out of Dicerna Pharmaceuticals, Inc. (DRNA) in Q4 2021, closing a stake of 227,187 shares — an estimated $4.58M sold.

Federated Hermes first reported a position in DRNA in Q1 2015 and held it in 19 quarters. The position peaked at $14.7M in Q2 2021. 1 fund tracked by Wall St. Rank holds DRNA as of Q4 2021.

  • Federated Hermes reported no remaining Dicerna Pharmaceuticals, Inc. position as of Q4 2021 after selling out during the quarter.
  • Federated Hermes sold 227,187 Dicerna Pharmaceuticals, Inc. shares in Q4 2021, an estimated $4.58M.
  • Federated Hermes first reported a position in Dicerna Pharmaceuticals, Inc. in Q1 2015 and held it in 19 quarters.
  • Federated Hermes's Dicerna Pharmaceuticals, Inc. position peaked at $14.7M in Q2 2021.
  • 1 fund tracked by Wall St. Rank held Dicerna Pharmaceuticals, Inc. as of Q4 2021.

Based on Federated Hermes's 13F filing for Q4 2021, filed 14 Feb 2022.